相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cell death pathways: intricate connections and disease implications
Matthias Kist et al.
EMBO JOURNAL (2021)
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax
Mario L. Marques-Piubelli et al.
LEUKEMIA & LYMPHOMA (2021)
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Xiang Zhang et al.
BIOMARKER RESEARCH (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
Piers Blombery et al.
BLOOD (2020)
Breaking through BCL-2 inhibition in CLL
Stephen J. F. Chong et al.
BLOOD (2020)
Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML
Myriam Hormi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Haijiao Zhang et al.
NATURE CANCER (2020)
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M. Moujalled et al.
LEUKEMIA (2019)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM
Florian Huemer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W. Roberts et al.
BLOOD (2019)
Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
Eugen Tausch et al.
HAEMATOLOGICA (2019)
Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis
Hendrik Folkerts et al.
CELL DEATH & DISEASE (2019)
Quest of biomarkers for venetoclax-treated CLL
Davide Rossi
BLOOD (2019)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Richard W. Birkinshaw et al.
NATURE COMMUNICATIONS (2019)
Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
Qingfang Li et al.
FRONTIERS IN PHARMACOLOGY (2019)
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Romain Guieze et al.
CANCER CELL (2019)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
CANCER DISCOVERY (2019)
BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
Benoit Tessoulin et al.
FRONTIERS IN ONCOLOGY (2019)
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea et al.
BLOOD ADVANCES (2019)
Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia
Elisabete do Vale Campos et al.
HEMATOLOGY TRANSFUSION AND CELL THERAPY (2019)
Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
Brenda Chyla et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Steven Coutre et al.
BLOOD (2018)
Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
Mohamed Rahmani et al.
CANCER RESEARCH (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
BCL-2 inhibition in AML: an unexpected bonus?
Marina Konopleva et al.
BLOOD (2018)
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
Ryan S. Soderquist et al.
NATURE COMMUNICATIONS (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells
Martin Grundy et al.
Oncotarget (2018)
Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
Joel D. Leverson et al.
FRONTIERS IN ONCOLOGY (2018)
Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment
Haijiao Zhang et al.
BLOOD (2018)
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero et al.
CELL DEATH AND DIFFERENTIATION (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies Genome Editing Techniques and Their Therapeutic Applications
A. W. Roberts et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
Monica Pallis et al.
ONCOTARGET (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pathways and mechanisms of venetoclax resistance
Prithviraj Bose et al.
LEUKEMIA & LYMPHOMA (2017)
DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
Mateus Milani et al.
CELL DEATH & DISEASE (2017)
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
Joyoti Dey et al.
SCIENTIFIC REPORTS (2017)
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Benjamin L. Lampson et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
CLINICAL CANCER RESEARCH (2017)
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Mary Ann Anderson et al.
BLOOD (2017)
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Stephen K. Tahir et al.
BMC CANCER (2017)
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo
Emma M. Carrington et al.
CELL DEATH AND DIFFERENTIATION (2017)
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells
Peter P. Ruvolo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Sina Oppermann et al.
BLOOD (2016)
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson et al.
BLOOD (2016)
BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
Michael Butterworth et al.
BRITISH JOURNAL OF CANCER (2016)
Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding
Ting Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Sarka Pospisilova et al.
HAEMATOLOGICA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The evolving potential of companion diagnostics
Joseph D. Khoury
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2016)
Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Sarka Pospisilova et al.
HAEMATOLOGICA (2016)
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Alex R. D. Delbridge et al.
NATURE REVIEWS CANCER (2016)
Next-Generation Companion Diagnostics Promises, Challenges, and Solutions
Joseph D. Khoury et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Sarah E. Alford et al.
CANCER RESEARCH (2015)
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Christopher J. Gibson et al.
CLINICAL CANCER RESEARCH (2015)
Resistance to ABT-199 induced by microenvironmental signals in chronic iymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
Rachel Thijssen et al.
HAEMATOLOGICA (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies
Jane Huang et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
Gaurav S. Choudhary et al.
ONCOTARGET (2015)
Resistance to ABT-199 induced by microenvironmental signals in chronic iymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
Rachel Thijssen et al.
HAEMATOLOGICA (2015)
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
X. Niu et al.
LEUKEMIA (2014)
Targeting the apoptosis pathway in hematologic malignancies
Shadia Zaman et al.
LEUKEMIA & LYMPHOMA (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go
Anna Puiggros et al.
BIOMED RESEARCH INTERNATIONAL (2014)
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
Meike Vogler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S. Davids et al.
BLOOD (2012)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
Asher A. Chanan-Khan et al.
LEUKEMIA & LYMPHOMA (2009)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
miR-15 and miR-16 induce apoptosis by targeting BCL2
A Cimmino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression
JD Khoury et al.
JOURNAL OF PATHOLOGY (2003)
分享论文
